News

What’s Happening With Amgen Stock?
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...
Fierce Biotech17h
Amgen rolls out phase 3 dosing plan for lead obesity candidate after midstage trial sees high discontinuation, vomiting rates
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
Pharmabiz15m
Amgen announces phase 2 obesity study results of MariTide; presents at 85th American Diabetes Association Scientific Sessions
Thousand Oaks, California Wednesday, June 25, 2025, 13:00 Hrs [IST] ...
BioPharma Dive15h
New Amgen obesity drug data disappoint Wall Street
Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...
STAT1d
Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Where Amgen Stands With Analysts
Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...
Dallas Goedert talks all things Eagles after winning Super Bowl LIX
Eagles tight end Dallas Goedert stops by to talk all things Eagles, another year of TEU and his partnership with Amgen.
American Express, Amgen share losses contribute to Dow's 100-point drop
Shares of American Express and Amgen are retreating Monday afternoon, dragging the Dow Jones Industrial Average into negative territory. Shares of American Express and Amgen are contributing to the ...